New pill tested for Tough-to-Treat breast cancer
NCT ID NCT05187832
Summary
This is the first study in people to test a new oral drug called AND019. It aims to find a safe dose and see early signs of whether it can help control advanced breast cancer that has stopped responding to standard hormone therapies. The study will enroll about 61 postmenopausal women whose cancer is estrogen receptor-positive and HER2-negative.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sarah Cannon Research Institute
RECRUITINGNashville, Tennessee, 37203, United States
Conditions
Explore the condition pages connected to this study.